[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Attikon Hospital\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":351},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,13,0,[8,46,79,104,124,146,166,194,217,244,270,291,316],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100639891","impact-of-glp-1-receptor-agonists-on-dry-eye-disease-in-patients-with-type-2-diabetes-mellitus-and-obesity-100639891",false,"NCT07605572","Impact of GLP-1 Receptor Agonists on Dry Eye Disease in Patients With Type 2 Diabetes Mellitus and Obesity","GALENOS","Inclusion Criteria:\n\n1. Age ≥18 years.\n2. Patients who have not previously received GLP-1 receptor agonists (GLP-1 RAs).\n3. Patients able to provide informed consent for participation in the study.\n\nExclusion Criteria:\n\n1. Pregnant or breastfeeding patients.\n2. History of multiple severe hypoglycemic episodes within the past two years.\n3. Active intraocular inflammation in either eye, such as infectious conjunctivitis, keratitis, scleritis, endophthalmitis, or autoimmune uveitis.\n4. Patients who have undergone cataract surgery or vitrectomy within the past 6 months.\n5. History of ketoacidosis or metabolic acidosis.\n6. History of corneal transplantation.","ALL","18 Years",{"count":19,"type":20},100,"ESTIMATED","OBSERVATIONAL","Diabetes mellitus (DM), prediabetes, and obesity are emerging as major global public health problems, with their epidemic spread continuously increasing over the past decades. The occurrence of diabetic retinopathy, cataract, glaucoma, and ocular surface disease in patients with diabetes mellitus has been extensively investigated in several studies. However, mild ocular surface disorders, such as dry eye disease, have often been overlooked, with a previous study showing that 51.3% of diabetes-related dry eye disease cases remained underdiagnosed. Among systemic diseases, diabetes mellitus and obesity have been associated with an increased risk of developing dry eye disease. Chronic hyperglycemia in diabetes leads to microvascular damage, including corneal neuropathy and reduced tear production, conditions that can disrupt ocular surface health, while systemic inflammation and meibomian gland dysfunction also contribute to this process. However, the effect of newer classes of antidiabetic medications, including glucagon-like peptide-1 receptor agonists (GLP-1 RAs), on ocular surface health remains insufficiently understood. The aim of this prospective cohort study is to evaluate the effects of GLP-1 receptor agonists on dry eye disease in patients with type 2 diabetes mellitus and obesity through the assessment of ocular surface parameters, such as tear film break-up time, Schirmer test results, as well as potential changes in corneal topography.",[24,25,26,27,28,29],"Dry Eye Disease (DED)","Diabete Mellitus","GLP-1","Ocular Surface","Diabetes Type 2","Cornea",[31,28,32,29],"Dry eye disease","GLP-1 Receptor Agonists","RECRUITING","2026-05-29",{"date":36,"type":37},"2026-06-02","ACTUAL",{"date":39,"type":37},"2026-03-01",{"date":41,"type":20},"2027-02-28",{"name":43,"class":44},"Attikon Hospital","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":66,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":45},"100625655","cryoneurolysis-prior-to-total-knee-arthroplasty-cryo-tka-trial-100625655","NCT07425457","Cryoneurolysis Prior to Total Knee Arthroplasty (CRYO-TKA Trial)","Association of Pre-operative Genicular Nerves Cryoneurolysis With Improved Pain and Function in Patients Undergoing Total Knee Arthroplasty","CRYO-TKA","Inclusion Criteria:\n\n* Adults ≥18 years undergoing primary TKA for osteoarthritis.\n* Cognitively normal and able to self-assess pain and function.\n* Provide written informed consent.\n\nExclusion Criteria:\n\n* Cancer-related knee pain.\n* Neurological, psychiatric, or medical conditions interfering with assessment.\n* Chronic opioid users.",{"count":19,"type":20},"INTERVENTIONAL",[57],"NA","Approximately 20-30% of patients experience persistent pain after a Total Knee Arthroplasty (TKA). This study investigates whether percutaneous cryoneurolysis of genicular nerves can reduce pain and improve physical function when performed at least 24 hours before surgery. Participants will be randomized to receive either the cryoneurolysis procedure + TKA or TKA only. Results will be tracked for 6 months to see if the intervention improves long-term recovery and quality of life.",[60,61,62,63,64,65],"Arthroplasty","Replacement Material","Knee Arthritis Osteoarthritis","Knee Arthroplasty, Total","Genicular Nerves","Chronic Pain",[67,68,69,70],"Cryoneurolysis","Interventional Radiology","Pain Management","Post-operative recovery","2026-02-19",{"date":73,"type":37},"2026-02-20",{"date":75,"type":37},"2026-01-02",{"date":77,"type":20},"2028-03-31",{"name":43,"class":44},{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":86,"minAge":17,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":45},"100584447","cardiovascular-and-endothelial-markers-during-ogtt-before-and-at-six-and-twelve-months-post-treatment-in-women-with-pcos-100584447","NCT06889454","Cardiovascular and Endothelial Markers During OGTT Before and at Six and Twelve Months Post-treatment in Women With PCOS","The Effect of Different Treatment Options on Markers of Vascular, Myocardial and Endothelial Function in Women With Polycystic Ovary Syndrome and the Association With Metabolic and Hormonal Abnormalities of the Syndrome","Inclusion Criteria:\n\n1. Age \\> 16 years old\n2. Diagonis of PCOS according to Rotterdam criteria: presence of two of the three of the following:\n\n   * Clinical or biochemical hyperandrogenism\n   * Anovulation or oligo-ovulation\n   * Polycystic ovarian morphology (PCOM)\n3. Absence of treatment for PCOS the last six months\n4. Patients who have the ability to understand and sign the consent form.\n\nExclusion Criteria:\n\n1. Disorders with clinical presentation similar to PCOS: thyroid disease, hyperprolactinemia, and non-classic congenital adrenal hyperplasia (primarily 21-hydroxylase deficiency by serum 17-hydroxyprogesterone \\[17-OHP\\]), Cushing syndrome, acromegaly\n2. Treatment with contraceptive or metformin\n3. Type 2 diabetes mellitus\n4. Treatment for diabetes\n5. Pregnancy\n6. Lactation\n7. Malignancy","FEMALE","45 Years",{"count":89,"type":20},120,"The aim of the present study is to investigate a) the presence of subclinical markers of vascular, myocardial and endothelial function in women with PCOS b) the acute alterations in these markers during the oral glucose tolerance test (OGTT) c) the impact of potential treatment interventions in these markers.",[92,93,94,95],"PCOS","Hyperinsulinism","Hyperandrogenism","Metabolic Syndrome","2025-11-15",{"date":98,"type":37},"2025-11-19",{"date":100,"type":37},"2024-02-01",{"date":102,"type":20},"2026-02-01",{"name":43,"class":44},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":4,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":110,"maxAge":111,"enrollmentInfo":112,"targetDuration":114,"studyType":21,"phases":4,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":118,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":45},"100565740","adherence-to-mediterranean-diet-in-type-1-diabetes-initiating-minimed-780g-glucose-metrics-vs-insulin-metrics-is-there-a-difference-100565740","NCT06646107","Adherence to Mediterranean Diet in Type 1 Diabetes Initiating Minimed 780G: Glucose Metrics vs Insulin Metrics, is There a Difference","Inclusion Criteria:\n\n1. Clinical diagnosis of type 1 diabetes \\>1 year prior to consent date. Diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not required.\n2. HbA1c \\\u003C 12.5%\n3. Age \\>7years at the initiation of the system\n4. Multiple Daily Injections (Basal Bolus therapy) with Total daily insulin use of great than 8.0 units per day over a 1-week period\n5. Clinically able to start the AHCL system\n6. History of 3 clinic visits in the last year\n\nExclusion Criteria:\n\n1\\. Diabetic Ketoacidosis in the 6 months prior to screening visits\n\n\\-","12 Years","80 Years",{"count":113,"type":20},240,"12 Months","In this observaltional study, 240 patients aged \\>12 years old with T1DM who are on multiple daily injections or insulin pump and are scheduled to start using MiniMed 780G system will be included.We aim to compare patients' adherence to Mediterranean diet (MD) before and 12 weeks after initiation of MiniMed 780G and its association with CGM and insulin metrics, as well as anthropometric measurements, BMI, body composition, lipid levels, blood pressure and gut microbioma. Moreover, at baseline, at six and 12 months, markers of endothelial and cardiovascular function will be also assessed and associated with the use of Minimed 780G and the adherence to MD.",[117],"Type1diabetes",{"date":98,"type":37},{"date":120,"type":37},"2025-03-01",{"date":122,"type":20},"2026-01-31",{"name":43,"class":44},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":131,"enrollmentInfo":132,"targetDuration":4,"studyType":55,"phases":134,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":138,"lastUpdatePostDateStruct":139,"startDateStruct":141,"completionDateStruct":143,"leadSponsor":145,"locationsCount":45},"100410757","effects-of-dexmedetomidine-on-intraocular-pressure-during-scheduled-spine-surgeries-100410757","NCT04628663","Effects of Dexmedetomidine on Intraocular Pressure During Scheduled Spine Surgeries","Effects of Systemic Administration of Dexmedetomidine on Intraocular Pressure During Scheduled Spine Surgeries in a Prone Position. Prospective, Randomized, Double-blinded Study.","Inclusion Criteria:\n\n* Adult patients undergoing scheduled spine surgery performed in prone position under general anaesthesia\n\nExclusion Criteria:\n\n* Patients who refuse to be a part of the study\n* Patients with previous eye surgery\n* Preexisting eye disease (e.g glaucoma)\n* Allergy to the study drug or any drug which is in the trial\n* Preoperative unstable hemodynamics","90 Years",{"count":133,"type":20},60,[57],"The aim of this study is to examine the effects of intraoperative systemic use of dexmedetomidine on the intraocular pressure (IOP) in patients undergoing spine surgeries in a prone position under general anesthesia.",[137],"Intraocular Pressure","2025-09-29",{"date":140,"type":37},"2025-09-30",{"date":142,"type":37},"2021-03-20",{"date":144,"type":20},"2026-05",{"name":43,"class":44},{"id":147,"slug":148,"hasResults":11,"nctId":149,"briefTitle":150,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":152,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":153,"targetDuration":154,"studyType":21,"phases":4,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":45},"100607624","the-value-of-eeg-in-stroke-units-100607624","NCT07190976","The Value of EEG in Stroke Units","Inclusion Criteria: Patients over 18 years of age with confirmed acute ischemic or hemorrhagic stroke are eligible for inclusion in the study. Patients whose clinical presentation mimics that of a stroke will be included until the diagnosis of stroke is ruled out, at which point they will be excluded from the study.\n\n\\-\n\nExclusion Criteria:\n\n\\-",true,{"count":19,"type":20},"2 Years","Τhe aim of the study is to investigate the role of EEG both in predicting epileptogenesis in patients with acute stroke and in detecting and clarifying the clinical significance of subclinical epileptic seizures in a stroke unit. More specifically, the performance of routine EEG in patients with ischemic or hemorrhagic stroke who are hospitalized in the Stroke Unit within the first days after the event, regardless of the presence of clinical indications, and the identification of risk factors for the early development of epilepsy in the course of these patients' disease constitute the central research question. The identification of patients with subclinical electroencephalographic seizures and the impact of such events on functional outcome, as well as their association with the development of epilepsy, are set as secondary research objectives.",[157],"Epilepsy","2025-09-17",{"date":160,"type":37},"2025-09-24",{"date":162,"type":37},"2024-03-01",{"date":164,"type":20},"2026-09-30",{"name":43,"class":44},{"id":167,"slug":168,"hasResults":11,"nctId":169,"briefTitle":170,"officialTitle":171,"acronym":4,"eligibilityCriteria":172,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":111,"enrollmentInfo":173,"targetDuration":4,"studyType":55,"phases":175,"briefSummary":176,"conditions":177,"keywords":180,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":193},"100482662","a-ketogenic-diet-as-a-complementary-treatment-on-patients-with-high-grade-gliomas-and-brain-metastases-100482662","NCT05564949","A Ketogenic Diet as a Complementary Treatment on Patients With High-grade Gliomas and Brain Metastases","A \"Classic\" Ketogenic Diet as a Complementary Therapeutic Management on Patients With High-grade Gliomas and Brain Metastases.","Inclusion Criteria:\n\n* Age 18-80\n* Karnofsky Performance Score of 50 or more.\n* Newly diagnosed, histologically confirmed glioblastoma grade 4, or secondary metastases or progression after surgical resection, radiation and chemotherapy.\n* Normal function of liver and kidneys\n* Ability to sign informed consent form\n\nExclusion Criteria:\n\n* Diabetes mellitus\n* Life expectancy \\>3 months\n* Inability to adhere to diet\n* Inability to give informed consent form\n* Cholecystectomy last 1 year (before the study entry)\n* Diagnosis of genetic disorder of fat metabolism",{"count":174,"type":20},15,[57],"The survival interval of patients with gliomas ranges between 12 to 15 months. Recent findings revealed that dietary interventions to reduce glucose and glycolytic pathways could have a therapeutic effect. Ketosis can be an effective therapy to extend the survival of patients with gliomas.",[178,179],"Brain","Cancer",[181,182,183,184],"ketogenic","diet","gliomas","metastases","2025-05-27",{"date":187,"type":37},"2025-05-31",{"date":189,"type":37},"2022-09-20",{"date":191,"type":20},"2026-02-28",{"name":43,"class":44},2,{"id":195,"slug":196,"hasResults":11,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":202,"enrollmentInfo":203,"targetDuration":4,"studyType":55,"phases":205,"briefSummary":206,"conditions":207,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":209,"lastUpdatePostDateStruct":210,"startDateStruct":212,"completionDateStruct":214,"leadSponsor":216,"locationsCount":45},"100524080","nol-guided-analgesia-during-elective-laparoscopic-surgery-under-general-anesthesia-100524080","NCT06104059","NOL Guided Analgesia During Elective Laparoscopic Surgery Under General Anesthesia","Ιntraoperative Administration of Opioids Guided by the Nociception Level Index NOL in Elective Laparoscopic Surgeries Under General Anesthesia: Effect on Opioid Consumption, Post-operative Pain and Patient Recovery","NOLGADELS","Inclusion Criteria:\n\n* Adult patients undergoing planned laparoscopic surgery under general anesthesia.\n\nExclusion Criteria:\n\n* Emergency surgery.\n* Pregnancy.\n* Drug or alcohol abuse in the last 6 months.\n* Chronic opioid use or patients with chronic pain.\n* Serious comorbidity \\[cardiac disease (atrial fibrillation, ventricular arrhythmias), liver or kidney disease\\]\n* Obesity (BMI \\>35).\n* Permanently implanted pacemaker.\n* Patients with CNS disease.\n* Allergy to any of the study drugs.\n* Patients receiving anticholinergics agonists, α2-adrenergic agonists, β1-adrenergic antagonists, antiarrhythmic drugs.","70 Years",{"count":204,"type":20},50,[57],"The aim of this study is to investigate the hypothesis that the intraoperative use of the nociception level index NOL can reduce opioid consumption in adult patients undergoing elective laparoscopic surgeries under general anesthesia, as well as to explore its effect on post-operative pain and patient recovery.",[208],"Intraoperative Analgesia","2025-03-30",{"date":211,"type":37},"2025-04-03",{"date":213,"type":37},"2023-04-20",{"date":215,"type":20},"2026-09-20",{"name":43,"class":44},{"id":218,"slug":219,"hasResults":11,"nctId":220,"briefTitle":221,"officialTitle":222,"acronym":4,"eligibilityCriteria":223,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":224,"enrollmentInfo":225,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":226,"conditions":227,"keywords":233,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":45},"100586242","gwas-to-identify-predictive-genetic-factors-for-the-success-of-dietary-intervention-in-the-treatment-of-ibs-symptoms-100586242","NCT06912828","GWAS to Identify Predictive Genetic Factors for the Success of Dietary Intervention in the Treatment of IBS Symptoms","Whole Genome Association Study (GWAS) to Identify Predictive Genetic Factors for the Success of Dietary Intervention in the Treatment of Irritable Bowel Syndrome (IBS) Symptoms","Inclusion Criteria:\n\n* Fulfillment of the Rome IV criteria for IBS\n* Provision of written informed consent.\n* Commitment of availability throughout the study period.\n* IBS-SSS \\> 175\n\nExclusion Criteria:\n\n* Any concomitant disease requiring specialized nutrition (e.g. renal failure, diabetes, celiac disease, cerebrovascular disease of the central nervous system, major surgical cavity).\n* Pregnancy.\n* Breastfeeding.","65 Years",{"count":19,"type":20},"This is a GWAS that aims to identify possible single nucleotide polymorphisms (SNPs) that are associated with the response in a combined dietary pattern low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols and Meditteranean diet (MED-LFD) in a small group of patients with Irritable Bowel Syndrome (IBS).",[228,229,230,231,232],"Irritable Bowel Syndrome (IBS)","Genome-wide Association Study","Single Nucleotide Polymorphisms","Mediterranean Diet","FODMAP Diet",[234,235],"diet response","nutrigenetics","2025-03-29",{"date":238,"type":37},"2025-04-06",{"date":240,"type":37},"2024-09-15",{"date":242,"type":20},"2027-02-15",{"name":43,"class":44},{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":11,"sex":86,"minAge":17,"maxAge":251,"enrollmentInfo":252,"targetDuration":4,"studyType":55,"phases":253,"briefSummary":254,"conditions":255,"keywords":257,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":45},"100315162","dexmedetomidine-wound-infiltration-in-cesarean-section-100315162","NCT03382938","Dexmedetomidine Wound Infiltration in Cesarean Section","Wound Infiltration With Dexmedetomidine in Cesarean Section: Effect on Postoperative Analgesia","Inclusion Criteria:\n\n* pregnancy \\>37 weeks, ASA I-II, BMI\\\u003C35\n\nExclusion Criteria:\n\n* patient refusal, epilepsy, GERD, morbid obesity, drug allergy, ASA class \\>2, presence of atrioventricular block, severe systemic disease, multiple gestation, high risk pregnancy, contraindications to epidural technique, a history of severe systemic disease, recreational drug or alcohol use","40 Years",{"count":19,"type":20},[57],"The effects of four different wound infiltration protocols in cesarean section will be investigated on parturient' pain intensity, PCA morphine consumption given, side effects and parturient' overall satisfaction.\n\nOne group will receive for wound infiltration dexmedetomidine, the second ropivacaine, the third dexmedetomidine combined with ropivacaine, while the last one will receive normal saline (placebo group).",[256],"Postoperative Pain",[258,259,260,261],"dexmedetomidine","ropivacaine","wound infiltration","ceasarean section","2025-03-16",{"date":264,"type":37},"2025-03-19",{"date":266,"type":37},"2019-08-23",{"date":268,"type":20},"2026-11-20",{"name":43,"class":44},{"id":271,"slug":272,"hasResults":11,"nctId":273,"briefTitle":274,"officialTitle":275,"acronym":4,"eligibilityCriteria":276,"healthyVolunteers":11,"sex":16,"minAge":110,"maxAge":111,"enrollmentInfo":277,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":279,"conditions":280,"keywords":4,"overallStatus":282,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":4},"100578392","the-association-between-time-in-range-with-markers-of-endothelial-and-cardiovascular-function-100578392","NCT06810700","The Association Between Time in Range With Markers of Endothelial and Cardiovascular Function","The Association Between Time in Range With Markers of Endothelail an Dcardiovascular Function in Patients With type1 Diabetes Mellitus and Minimed 780G","Inclusion Criteria:\n\n1. Clinical diagnosis of type 1 diabetes \\>1 year prior to consent date. Diagnosis of type 1 diabetes is based on the investigator's judgment; C peptide level and antibody determinations are not required.\n2. HbA1c \\\u003C 12.5%\n3. Age \\>7years at the initiation of the system\n4. Multiple Daily Injections (Basal Bolus therapy) with Total daily insulin use of great than 8.0 units per day over a 1-week period\n5. Clinically able to start the AHCL system\n6. History of 3 clinic visits in the last year\n\nExclusion Criteria:\n\n1\\. Diabetic Ketoacidosis in the 6 months prior to screening visits",{"count":278,"type":20},90,"In this observaltional study, 90 patients aged \\>12 years old with T1DM who are on MiniMed 780G system will be included.We aim to investigate the association between time in range (70-140mg\u002Fdl) and time in tight range (70-180mg\u002Fdl) with markers of endothelial and cardiovascular function.",[281],"Type 1 Diabetes","NOT_YET_RECRUITING","2025-02-04",{"date":285,"type":37},"2025-02-05",{"date":287,"type":20},"2025-02-15",{"date":289,"type":20},"2025-09-15",{"name":43,"class":44},{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":224,"enrollmentInfo":298,"targetDuration":4,"studyType":55,"phases":300,"briefSummary":301,"conditions":302,"keywords":304,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":315,"locationsCount":193},"100573694","digestive-enzyme-formulation-intervention-in-ibs-patients-who-previously-clinically-responded-to-mediterranean-lfd-100573694","NCT06749613","Digestive Enzyme Formulation Intervention in IBS Patients Who Previously Clinically Responded to Mediterranean LFD","Digestive Enzyme Formulation Intervention in Irritable Bowel Syndrome Patients Who Previously Clinically Responded to Mediterranean Low FODMAP Diet: A Single-Arm Clinical Trial","Inclusion Criteria:\n\n* Provision of written informed consent.\n* Commitment to availability throughout the study period.\n* Patients who fulfilled the Rome IV criteria for IBS (IBS-D, IBS-M, IBS-U) participated in the two-arm clinical trial (ClinicalTrials.gov ID: NCT03997708) as responders to the Mediterranean Diet Adjusted to Low FODMAP (MED-LFD) (if their symptoms recurred -with IBS-SSS \\> 175- one year after their initial response to the dietary intervention).\n* Subjects randomized to the MED-LFD arm of the previous study who could not adhere to the dietary intervention.\n\nExclusion Criteria:\n\n* Patients who did not take part in the aforementioned study\n* Patients who were randomized in the NICE group\n* Patients with IBS-SSS\\\u003C175.",{"count":299,"type":20},40,[57],"Irritable bowel syndrome (IBS) is a highly prevalent chronic functional gastrointestinal disorder. The cardinal symptoms include abdominal pain, flatulence, bloating, and changes in bowel habits related to stool frequency and consistency, in the absence of detectable structural and biochemical abnormalities1,2. The prevalence is estimated at 5-10% among different ethnicities3. A low FODMAP diet is the most common dietary intervention with clinically proven benefits in symptom management and quality of life improvement of patients with Irritable Bowel Syndrome (IBS)4. Recently, a dietary digestive enzyme formulation (FODZYME©) claims similar efficacy in symptom management based on an ex-vivo study5. The study aims to examine the clinical efficacy of this formulation in managing IBS symptoms in patients who have previously clinically responded to a low FODMAP diet.",[303],"Irritable Bowel Syndrome",[305,306,307],"low FODMAP Diet","MED-LFD","digestive enzymes","2025-01-06",{"date":310,"type":37},"2025-01-07",{"date":312,"type":37},"2024-12-10",{"date":314,"type":20},"2026-03-30",{"name":43,"class":44},{"id":317,"slug":318,"hasResults":11,"nctId":319,"briefTitle":320,"officialTitle":320,"acronym":4,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":322,"targetDuration":323,"studyType":21,"phases":4,"briefSummary":324,"conditions":325,"keywords":328,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":350,"locationsCount":45},"100541501","prospective-evaluation-of-ultrasound-guided-percutaneous-cholecystostomy-with-the-trocar-technique-100541501","NCT06330688","Prospective Evaluation of Ultrasound-guided Percutaneous Cholecystostomy With the Trocar Technique","Inclusion Criteria:\n\n* All patients requiring PC, irrespective of the underlying cause and indication, are suitable for inclusion in the study.\n\nExclusion Criteria:\n\n* Patients are going to be excluded from the study if they are younger than 18 years, if they require PC catheter placement under CT guidance (according to the operator's judgement), or if they suffer from severe uncontrollable coagulopathy.",{"count":19,"type":20},"3 Months","The purpose of this study is to further evaluate and investigate the safety and efficacy of ultrasound (US)-guided percutaneous cholecystostomy (PC) with the trocar technique by the patient's bedside.",[326,327],"Cholecystitis, Acute","Cholecystitis",[329,330,331,332,333,334,335,336,337,338,339,340,341,342],"cholecystostomy","percutaneous","trocar","ultrasound","guided","technique","Seldinger","transhepatic","transperitoneal","subcostal","intercostal","technical","success","complications","2024-03-19",{"date":345,"type":37},"2024-03-26",{"date":347,"type":20},"2024-03",{"date":349,"type":20},"2026-06",{"name":43,"class":44},""]